ARCA biopharma, Inc. (ABIO)
After hours:
| Previous Close | 3.0700 |
| Open | 3.0200 |
| Bid | 3.0800 x 100 |
| Ask | 3.2000 x 100 |
| Day's Range | 3.0100 - 3.2899 |
| 52 Week Range | 1.5600 - 4.4900 |
| Volume | |
| Avg. Volume | 97,663 |
| Market Cap | 45.552M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings Date | Jul 26, 2024 - Aug 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Insider MonkeyWhy Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)?
We recently compiled a list of What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting. In this article, we are going to take a look at where ARCA Biopharma, Inc. (NASDAQ:ABIO) stands against the other stocks hedge funds are shorting. Short selling, also known as shorting or going short, is a […]
GlobeNewswireARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee o
GlobeNewswireARCA biopharma and Oruka Therapeutics Announce Merger Agreement
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations thr
